<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02101125</url>
  </required_header>
  <id_info>
    <org_study_id>IM136-122</org_study_id>
    <nct_id>NCT02101125</nct_id>
  </id_info>
  <brief_title>Drug Interaction Study With Rosuvastatin</brief_title>
  <official_title>A Phase 1 Open-label, Single-sequence Study to Evaluate the Effect of Concomitant Administration of BMS-986020 on the Single-dose Pharmacokinetics of Rosuvastatin in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of concomitant administration of&#xD;
      BMS-986020 on the single dose Pharmacokinetics (PK) of Rosuvastatin in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half-life (T-HALF) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F) of Rosuvastatin with and without coadministered BMS-986020</measure>
    <time_frame>31 timepoints up to Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Event (AEs), Serious Adverse Event (SAEs), deaths, and AEs leading to discontinuation</measure>
    <time_frame>Upto Day 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Results of vital signs, ECGs, Physical Examination (PEs), and clinical lab result</measure>
    <time_frame>Up to Day 12</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Immunosuppression For Disease</condition>
  <arm_group>
    <arm_group_label>BMS-986020 + Rosuvastatin (Treatment A, B and C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days&#xD;
Cohort 2 (Administered 4 hrs, after the morning dose of BMS-986020): Rosuvastatin Tablet Single dose and BMS- 986020 orally on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986020</intervention_name>
    <arm_group_label>BMS-986020 + Rosuvastatin (Treatment A, B and C)</arm_group_label>
    <other_name>Lysophosphatidic acid (LPA1) Antagonist</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>BMS-986020 + Rosuvastatin (Treatment A, B and C)</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit&#xD;
        www.BMSStudyConnect.com.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects who have no clinically significant deviation from normal in medical&#xD;
             history, surgical history, PE, vital signs, ECG, and clinical laboratory&#xD;
             determinations&#xD;
&#xD;
          -  Nonsmokers&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18.0 to 32.0 kg/m2, inclusive. Men, ages 18 to 50 years,&#xD;
             inclusive&#xD;
&#xD;
          -  Men and women, ages 18 to 50 years, inclusive&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy&#xD;
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to&#xD;
             the start of investigational product&#xD;
&#xD;
          -  Men who are sexually active with WOCBP must agree to follow instructions for method(s)&#xD;
             of contraception for the duration of treatment with study drug(s) (11 days) plus 5&#xD;
             half-lives of the study drug (4 days) plus 90 days (duration of sperm turnover) for a&#xD;
             total of 94 days posttreatment completion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant acute or chronic medical illness&#xD;
&#xD;
          -  Current or recent (within 3 months of study drug administration) gastrointestinal&#xD;
             disease&#xD;
&#xD;
          -  Any major surgery within 4 weeks of study drug administration&#xD;
&#xD;
          -  Any gastrointestinal surgery (eg, partial gastrectomy, pyloroplasty) including&#xD;
             cholecystectomy that could impact upon the absorption of study drug&#xD;
&#xD;
          -  Donation of &gt; 400 mL of blood within 8 weeks or donation of plasma (except at&#xD;
             screening visit) within 4 weeks of study drug administration&#xD;
&#xD;
          -  Blood transfusion within 4 weeks of study drug administration&#xD;
&#xD;
          -  Inability to tolerate oral medication&#xD;
&#xD;
          -  Inability to be venipunctured and/or tolerate venous access as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Use of tobacco-containing or nicotine containing products (including but not limited&#xD;
             to cigarettes, pipes, cigars, chewing tobacco, nicotine patches, nicotine lozenges, or&#xD;
             nicotine gum) within 6 months prior to check-in, or a positive nicotine test (ie,&#xD;
             cotinine) at screening or check-in&#xD;
&#xD;
          -  Subjects who drink more than 3 cups of coffee or other caffeine containing products&#xD;
             with an equivalent amount of caffeine per day, or 5 cups of tea per day&#xD;
&#xD;
          -  History of allergy to Lysophosphatidic acid (LPA1) antagonists or related compounds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Healthcare Discoveries, Llc D/B/A Icon Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>March 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2014</study_first_posted>
  <last_update_submitted>June 16, 2014</last_update_submitted>
  <last_update_submitted_qc>June 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

